Special Diabetes Program Reauthorization Act of 2025

Bill Number

S. 2211

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-07-08: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Last Updated

2026-01-29T12:03:17Z

AI-Generated Summary

Purpose

The Special Diabetes Program Reauthorization Act of 2025 aims to extend federal funding for two targeted public health initiatives: the Special Diabetes Program for Type 1 Diabetes, which supports research, prevention, and treatment of type 1 diabetes, and the Special Diabetes Program for Indians, which addresses diabetes prevention and care in Native American communities. These programs are administered through the U.S. Department of Health and Human Services (HHS) and help fund grants to organizations working on diabetes-related efforts.

Key Provisions

• Funding Extension for Type 1 Diabetes Program: Amends Section 330B of the Public Health Service Act to authorize:
• $160 million for each of fiscal years 2026 and 2027.
• $40 million for the period from October 1, 2027, to December 31, 2027.
• Funds remain available until spent, supporting research, care coordination, and education.
• Funding Extension for Indians Program: Amends Section 330C of the Public Health Service Act with identical funding levels:
• $160 million for each of fiscal years 2026 and 2027.
• $40 million for the period from October 1, 2027, to December 31, 2027.
• Focuses on diabetes prevention, treatment, and health services in Indian health programs.
• The bill was introduced by Senators Collins and Shaheen on July 8, 2025, and referred to the Senate Committee on Health, Education, Labor, and Pensions.

Significant Changes to Existing Law

• Extends the authorization of appropriations for both programs through the end of 2027, building on prior funding levels (previously set through fiscal year 2024 in earlier reauthorizations).
• Adds new subparagraphs (H and I) to the existing funding schedules in the Public Health Service Act, increasing the total funding horizon without altering program structures or eligibility rules.
• Maintains the "available until expended" clause, allowing flexibility in spending beyond the fiscal year.

Potential Impacts

• On Government Agencies: Provides HHS with continued budget authority to distribute grants, potentially stabilizing operations for diabetes research and Native American health services without immediate funding cliffs.
• On Citizens: Enhances access to diabetes care, research advancements, and preventive services, particularly benefiting the 1.6 million Americans with type 1 diabetes and Native American populations, where diabetes rates are up to four times higher than the general population.
• On International Relations: Minimal direct impact, as the programs are domestic-focused, though research outcomes could indirectly influence global diabetes knowledge-sharing.

Main Stakeholders Affected

• Patients and Communities: Individuals with type 1 diabetes and Native Americans facing high diabetes prevalence, including tribal members served by Indian Health Service facilities.
• Healthcare and Research Entities: Non-profit organizations, universities, and medical centers receiving grants for diabetes studies, clinical trials, and community health programs.
• Government Bodies: HHS and its divisions (e.g., Centers for Disease Control and Prevention, National Institutes of Health), as well as tribal governments and health organizations.
• Advocacy Groups: Diabetes foundations and Native American health coalitions that rely on program funding for advocacy and implementation.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens continuity of public health funding under the Public Health Service Act without introducing new regulatory burdens; ensures compliance with federal grant-making processes.
• Constitutional: Aligns with Congress's spending power under Article I, Section 8, to promote general welfare through targeted health programs; no apparent conflicts with federalism, as it supports voluntary state and tribal partnerships.
• Political: Demonstrates bipartisan support (introduced by senators from different parties) for chronic disease management, potentially influencing future health funding debates amid rising healthcare costs; could set precedent for short-term extensions in budget-constrained environments, risking lapses if not renewed beyond 2027.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Collins, Susan M. [R-ME]

Cosponsors (34)

Sen. Shaheen, Jeanne [D-NH], Sen. Hyde-Smith, Cindy [R-MS], Sen. Murkowski, Lisa [R-AK], Sen. Sullivan, Dan [R-AK], Sen. Warnock, Raphael G. [D-GA], Sen. Cortez Masto, Catherine [D-NV], Sen. Merkley, Jeff [D-OR], Sen. Capito, Shelley Moore [R-WV], Sen. Rosen, Jacky [D-NV], Sen. Murray, Patty [D-WA], Sen. Booker, Cory A. [D-NJ], Sen. Duckworth, Tammy [D-IL], Sen. Moran, Jerry [R-KS], Sen. Coons, Christopher A. [D-DE], Sen. Bennet, Michael F. [D-CO], Sen. Blunt Rochester, Lisa [D-DE], Sen. Welch, Peter [D-VT], Sen. Marshall, Roger [R-KS], Sen. Gallego, Ruben [D-AZ], Sen. Kelly, Mark [D-AZ], Sen. Heinrich, Martin [D-NM], Sen. Husted, Jon [R-OH], Sen. Van Hollen, Chris [D-MD], Sen. Risch, James E. [R-ID], Sen. Kennedy, John [R-LA], Sen. Luján, Ben Ray [D-NM], Sen. Schiff, Adam B. [D-CA], Sen. Peters, Gary C. [D-MI], Sen. Warner, Mark R. [D-VA], Sen. Britt, Katie Boyd [R-AL], Sen. Wicker, Roger F. [R-MS], Sen. Durbin, Richard J. [D-IL], Sen. Slotkin, Elissa [D-MI], Sen. Alsobrooks, Angela D. [D-MD]

Recent Actions

• 2025-07-08: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
• 2025-07-08: Introduced in Senate

Bill Versions

• Special Diabetes Program Reauthorization Act of 2025 — issued 2025-07-08 — PDF (3 pages)